Module 1 Key: Flashcards

1
Q

The only type of research that can establish a causal link between the exposure and the effect.

A

When properly executed, a clinical trial can establish a causal link between the exposure and the effect.

This is the only way, through a clinical trial. The best! Because you are testing on humans, real world.

it would be possible to conclude that the experimental treatment controls blood pressure better than standard treatment in patients with hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

RCT studies are generally prospective. What does that mean?

A

participants are recruited, treated, and followed for a certain time in order to evaluate the evolution of their state of health.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

True or False:
(Biomedical) science before statistics, not the other way around.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When would it be unethical to use a placebo?

A

when there are other effective interventions, it is often unethical to use a placebo as a comparator: Concept of comparing to Standard of Care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe PICODE

A
  • P: Population
  • I: Intervention
  • C: Control
  • O: Main clinical outcome (O for “outcome” in English).Primary outcome endpoint (PRC)of the study.
  • D: Area of Application (Therapeutic, Prevention, Depistage)
  • E: design d’étude (randomisée, cohorte, observationnelle, double blind)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thérapeutique, prevention vs depistage types of participants

A

Thérapeutique: patients atteints d’une maladie
Prévention and depistage: participants en santé

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe what this means:
À noter que non-inférieur ne veut pas dire équivalent.

A

Un traitement équivalent n’est ni inférieur et ni supérieur par rapport à l’autre. Par contre, un traitement non-inférieur pourrait être supérieur au traitement standard.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does this describe;

Prévenir ou reporter la progression de la maladie

A

Dépistage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does this describe:
Prévenir ou reporter les conséquences de la maladie.

A

Thérapeutique
Prévenir ou reporter les conséquences de la maladie ou la guérir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Generally speaking, for what group are the risks more tolerated?

A

For very sick patients

Generally speaking, the risks are more or less acceptable depending on the therapeutic area.For example, significant adverse effects (e.g. hair loss) will be tolerated for terminally ill cancer patients if the intervention could double or triple survival.But this would not be tolerated for much less severe medical conditions (e.g. hypertension).

For therapeutic you are more likely to allow a higher risk but for screening and prevention (healthy people) the risk is less tolerated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Would this require approval of Health Canada:
aspirin (approved as an analgesic) used for the prevention of cardiovascular diseases

A

Yes.A claim for another disease leading to a change of indication will require new approval.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Would this require approval of Health Canada:
prevention of certain cancers with vitamin D supplements

A

Nope

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Can a vacinne or medication ever be used wihout approval?

A

Yes
In force majeure situations, such as a public health emergency (COVID-19), it is possible to allow the use of a vaccine or medicine before obtaining approval.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical trial phases. Phase 1 type of participants, number of participants and goal. What determines is you can go to Phase 2?

A
  • These participants are healthy
  • Given that these are the first evaluations in humans, we proceed very cautiously by exposing very few participants
  • The goal of a Phase I study is to detect common side effects. Phase I can be used to determine the maximum tolerated dose and the safe dose.
  • If the safety profile is acceptable, we will then proceed toPhase IIstudies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinical trial phases. Phase 2 type of participants, number of participants and goal. What determines is you can go to Phase 3?

A
  • Patients or people that can benefit from intervention
  • More people but not a huge amount
  • The objective of phase 2 is still safety (but in the** patients targeted by the treatment**) but we will also be interested in effectiveness.
  • If the safety profile remains acceptable, Phase IIIstudies will be carried out.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

True or False

Phase 2 can be used to determine uncomon adverse effects but nor rare.

What about phase 3?

A

False

Phase II studies cannot detect rare or uncommon adverse or serious effects.Phase 2 can be used to determine the optimal dose for Phase III studies.

Phase III studies cannot detect very rare adverse or serious effects

17
Q

Clinical trial phases. Phase 3 type of participants, number of participants and goal. What determines is you can go to Phase 4?

A
  • Patients or people that can benefit from intervention
  • More people but not a huge amount
  • Goal here effectiveness
18
Q

What is phase 4 of clinical trial?

A

Phase IV : études post-marketing. Ces études
observationnelles sont typiquement des registres d’effets indésirables observés chez les patients en
pratique clinique.

After phase 3, several million people will potentially use the new treatment.Phase IV studies therefore make it possible to establish the safety profile with more precision.

19
Q

What phases would you be able to skip if you want to show that aspirin can be used for cardiovascular disease?

A

Phase I and II studies are not always necessary: Aspirin

In the context of aspirin we already know its common side effects (Phase 1) and we have a good understanding of how it works in the body (Phase 2) but we do not know how it will work in a cohort with cardiovascular disease. So we can skip Phase 1 and 2 but need to do Pase 3 and 4.

20
Q

Describe this:

l’étude est dite «masquée », « à l’aveugle », ou « à l’insu ».

A

When the participant does not know which of several interventions he or she is receiving, the study is called “masked,” “blinded,” or “double-blinded.”

double-blinded: the clinical staff doesn;t know either

21
Q

Put these in order of decreasing strength:

Groupe d’experts publiant des opinions/éditoriaux dans les revues médicales
Étude/séries de cas
Étude cas-témoins
Étude de cohorte
Essai clinique randomisé
Revue systématique et méta-analyse

A
  1. Revue systématique et méta-analyse
  2. Put these in order of decreasing strength:
  3. Étude de cohorte
  4. Étude cas-témoins
  5. Étude/séries de cas
  6. Groupe d’experts publiant des opinions/éditoriaux dans les revues médicales
22
Q

What is external validity?

A

The generalization of the study

Say your cohort is for people from 20-40, well then you cannot generalize it for people over 40 or under 20.

23
Q

True or False

It is almost impossible to control all bias in an RCT , however, this control is possible with an epidemiological study.

A

False
It is almost impossible to control all bias in an epidemiological study, however, this control is possible with an RCT.

24
Q

True or False

Les évidences expérimentales peuvent provenir de revues systématiques et méta analyses. Les évidences observationnelles peuvent provenir d’études de cas, d’essais cliniques randomisés (ECR), d’études cas/témoin.

A

False
Les évidences observationnelles peuvent provenir d’études de cas, mais pas d’essais cliniques randomisés (ECR)

25
Q

True or False

Les études de Phase I et II permettent de détecter des effets indésirables ou néfastes associés au traitement peu fréquents ou rares.

A

FASLE

Phase II studies cannot detect rare or uncommon adverse or serious effects.